Polaris Pharmaceuticals
Polaris Group is a clinical-stage biopharmaceutical company developing ADI-PEG 20 (pegargiminase), a first-in-class arginine deprivation therapy for ASS1-deficient cancers, with FDA BLA review underway for mesothelioma. It also operates CDMO peptide and sterile injectable manufacturing through its Genovior and DesigneRx subsidiaries.
- Company typePublic
- Founded2006
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Polaris Pharmaceuticals does
Polaris Pharmaceuticals, operating as Polaris Group (TWSE: 6550), is a Cayman Islands-incorporated clinical-stage biopharmaceutical company founded in 2006 and headquartered in Taipei, with principal R&D operations in San Diego, California. The company is developing ADI-PEG 20 (pegargiminase, brand name ADZODI), a pegylated arginine deiminase biologic that depletes plasma arginine by converting it to citrulline. This selectively starves ASS1-deficient cancer cells, which cannot recycle citrulline back into arginine via the urea cycle, while sparing healthy cells. The lead indication, malignant pleural mesothelioma (MPM), is currently under FDA BLA substantive review following completion of rolling submission in June 2025, with Phase 3 ATOMIC-Meso data showing a four-fold improvement in 36-month survival published in JAMA Oncology. Polaris is also running Phase 2/3 trials in hepatocellular carcinoma, soft tissue sarcoma, and glioblastoma, plus Phase 1 in acute myeloid leukemia (where a 91.3% objective response rate was reported in December 2025) and Phase 2 in NASH.
Polaris operates a dual-engine business model. Engine one is the novel drug development pipeline, monetized through future drug sales and out-licensing to regional commercialization partners — Er-Kim (36 EMEA markets), Bioprofarma Bagó (Argentina/LATAM), and Tabuk (Saudi Arabia + 7 GCC countries). Engine two is a contract development and manufacturing organization (CDMO) business operated through wholly-owned subsidiaries Genovior Biotech Corporation (Taiwan) and DesigneRx Pharmaceuticals (Chengdu, China), which provide peptide API synthesis, sterile injectable fill-finish, and complex injectables to global pharmaceutical customers. Polaris also entered a non-exclusive distribution agreement with MNR Therapeutics in November 2025 for Fulvestrant commercialization in the GCC region.
The company owns three cGMP manufacturing sites: Vacaville, California (biologics manufacturing built in 2005); Chengdu, China (30,000 m² facility established in 2013, FDA/EMA/NMPA compliant); and a new Zhunan, Taiwan plant under construction since April 2025 as part of an NT$80 billion 2025–2029 capacity expansion. Polaris completed a NT$11.76 billion (approximately US$362 million) capital injection in December 2024 and a December 2025 private placement authorization of up to 150 million shares at NT$30 per share, both aimed at funding the dual-engine strategy and the GLP-1 peptide generic opportunity. The company is not yet profitable and does not pay dividends.
Polaris Pharmaceuticals firmographics
Firmographics- Name
- Polaris Pharmaceuticals
- Legal name
- Polaris Group
- Website
- https://polarispharma.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Polaris Group is a clinical-stage biopharmaceutical company developing ADI-PEG 20 (pegargiminase), a first-in-class arginine deprivation therapy for ASS1-deficient cancers, with FDA BLA review underway for mesothelioma. It also operates CDMO peptide and sterile injectable manufacturing through its Genovior and DesigneRx subsidiaries.
- Ownership category
- akta.pro rank
Polaris Pharmaceuticals industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industry
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where Polaris Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
Polaris Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Infrastructure, Personnel, Operations, Marketing or Sales
Revenue model
- New Drug Development (ADI-PEG 20): Polaris is a pre-revenue biopharmaceutical company developing ADI-PEG 20 (pegargiminase) for multiple cancer indications. The lead indication MPM (malignant pleural mesothelioma) is under FDA BLA substantive review. Revenue will come from drug sales upon regulatory approval.
- Regional Licensing and Distribution Revenue: Polaris out-licenses ADI-PEG 20 to regional partners (Er-Kim for EMEA, Bioprofarma Bagó for LATAM, Tabuk for GCC) who hold marketing rights and pay licensing fees, milestones, and potentially royalties on net sales.
- CDMO Services (Genovior and DesigneRx): Contract development and manufacturing services for peptide APIs and sterile injectables through subsidiaries Genovior Biotech Corporation and DesigneRx Pharmaceuticals Chengdu. Generates revenue from manufacturing fees, technology transfer, and contract services for global pharmaceutical customers.
- Fulvestrant Commercialization (Genovior/MNR): Genovior (via its parent Polaris Group) has a non-exclusive agreement with MNR Therapeutics for commercialization of Fulvestrant in GCC region, generating product supply and distribution revenue.
Go-to-market motion1 record
Distribution channels5 records
Marketing channels4 records
Polaris Pharmaceuticals product offering
Product offeringCore offering
Polaris Group is a multinational biopharmaceutical company developing ADI-PEG 20 (Pegargiminase/ADZODI), a first-in-class pegylated arginine deiminase biologic that selectively starves ASS1-deficient cancer cells of arginine. The drug is in late-stage clinical development across multiple oncology indications (malignant pleural mesothelioma, hepatocellular carcinoma, soft tissue sarcoma, glioblastoma, acute myeloid leukemia) and NASH. The company also operates a CDMO business through Genovior Biotech and DesigneRx Pharmaceuticals providing peptide API and sterile injectable contract manufacturing services.
Product overview
Polaris Group operates a dual-engine business strategy combining novel cancer drug development with contract manufacturing services. The core product is ADI-PEG 20 (Pegargiminase/ADZODI), a late-stage biologic cancer therapy that works through arginine deprivation. The drug is in FDA review for malignant pleural mesothelioma and undergoing Phase 2/3 trials for multiple other oncology indications including soft tissue sarcoma, glioblastoma, hepatocellular carcinoma, and acute myeloid leukemia. The second engine comprises CDMO operations through Genovior Biotech (peptide API and sterile injectables) and DesigneRx Pharmaceuticals Chengdu (biologics and peptide manufacturing), providing contract development and manufacturing services globally. Manufacturing facilities in California (Vacaville, San Diego) and Chengdu, China operate under FDA, EMA, and NMPA cGMP standards.
Differentiator
Problem solved
Functional benefit
Brands
- ADZODI: Brand name for ADI-PEG 20 (pegargiminase) for treatment of malignant pleural mesothelioma
Products and services
- ADI-PEG 20 (Pegargiminase/ADZODI) First-in-class pegylated arginine deiminase biologic that depletes plasma arginine by converting it to citrulline, selectively killing ASS1-deficient cancer cells while sparing healthy cells. In late-stage clinical development for malignant pleural mesothelioma, hepatocellular carcinoma, soft tissue sarcoma, glioblastoma, acute myeloid leukemia, and non-alcoholic steatohepatitis.
- CDMO Services (Contract Development and Manufacturing) Contract development and manufacturing services for biologics and peptide drugs including process development, scale-up, formulation development, and commercial production under FDA, EMA, and NMPA cGMP standards. Spans clinical sample production to commercial-scale manufacturing for global pharmaceutical customers.
- Fulvestrant Established endocrine therapy for hormone receptor positive (HR+)/HER2-negative advanced breast cancer in postmenopausal women. Supplied by Genovior to MNR Therapeutics for distribution in GCC region.
Quantifiable outcome
- Phase 1 AML trial: 91.3% overall objective response rate (21/23 evaluable patients); 69.6% complete response rate; 19.1 months median overall survival
- +3 more outcomes
Companies that use Polaris Pharmaceuticals
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Polaris Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Polaris Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and core.
- MNR TherapeuticsminorGenovior (Polaris subsidiary) and MNR Therapeutics (Switzerland) signed a non-exclusive agreement for distribution and commercialization of Fulvestrant in GCC countries. MNR handles market access and hospital channels in GCC while Genovior supplies the product. This expands Polaris's presence in GCC oncology treatment centers.
- Bioprofarma BagócorePolaris subsidiary PPI signed exclusive licensing agreement with Bioprofarma Bagó (a fully owned subsidiary of Grupo Empresarial Bagó in Buenos Aires, Argentina) to introduce ADI-PEG 20 (ADZODI) for treatment of MPM to Latin America. PPI develops and manufactures the product while Bioprofarma Bagó holds marketing authorization rights and is responsible for registration, import, and promotion in LATAM.
- Er-Kim PharmaceuticalscorePolaris subsidiary PPI signed exclusive distribution agreement with Er-Kim Pharmaceuticals for commercialization of ADI-PEG 20 (ADZODI) for malignant pleural mesothelioma (MPM) in EMEA (Europe, Middle East, Africa) across 36 markets. Er-Kim is responsible for sales and market access in these territories. The partnership aims to expand access to this innovative metabolic therapy in regions with unmet medical need.
- Tabuk PharmaceuticalscorePolaris subsidiary PPI signed exclusive partnership with Tabuk Pharmaceuticals (a fully owned subsidiary of Astra Industrial Group in Saudi Arabia) for ADI-PEG 20 (ADZODI) commercialization in Saudi Arabia and 7 GCC countries. Tabuk holds market authorization and handles registration, import, and promotion in the region, which has high unmet medical need for novel cancer therapies.
- Genovior Biotech Corporation (霖揚生技)corePolaris Group acquired 100% of Genovior Biotech Corporation (霖揚生技), a key subsidiary specializing in peptide API and sterile injectable CDMO services. Genovior brings proprietary fully synthetic peptide technology platform and sterile injection formulation capabilities. Its acquisition enables Polaris's dual-engine growth strategy combining novel drug development with CDMO services.
- Global Coalition for Adaptive Research (GCAR)corePolaris Group partnered with GCAR for inclusion of ADI-PEG 20 in the FDA-accepted GBM AGILE adaptive clinical trial platform. The platform enables simultaneous evaluation of multiple brain cancer drugs with shared control groups. This Phase 2/3 trial targets 300 patients globally and could serve as a direct pathway to regulatory approval.
- University of California Irvine (UCI) Vaccine Research CenterminorPolaris Group entered a corporate sponsored research agreement with UCI's Vaccine Research Center (led by Dr. Philip Felgner) to support development of Fluvid, a universal mRNA influenza and coronavirus vaccine. Polaris aims to leverage the mRNA vaccine technology for enhanced vaccine and cancer treatment development, targeting to become the first company in Taiwan with mRNA technology capabilities.
- Nanotein TechnologiesminorPolaris Group established a strategic partnership with Nanotein Technologies (San Francisco Bay Area startup) to advance Nanotein's protein-based cell therapy manufacturing solutions. Polaris Group collaborated on cell therapy development leveraging Nanotein's expertise. Nanotein later launched GROW-NK, an NK cell activation and expansion reagent that Polaris Group has strategic interest in.
Scale indicators10 records
Recent moves12 records
Expansion highlights5 records
Polaris Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- AGC Biologics: Global biologics CDMO offering mammalian and microbial expression and aseptic fill-finish. Comparable to Polaris for recombinant protein manufacturing (relevant to ADI-PEG 20 biologic) and CDMO services.
- Samsung Biologics: Korean biologics CDMO with large-scale mammalian cell culture capacity and expanding into peptide and sterile fill-finish. Comparable to Polaris's CDMO business in scope, Asian geography, and customer focus.
- WuXi Biologics: Asia-headquartered biologics CDMO with end-to-end capabilities from cell line development to commercial manufacturing. Direct peer to Polaris's Genovior and DesigneRx biologics/peptide CDMO services, with overlapping customer base.
- Bachem Holding AG: Leading peptide API manufacturer serving pharma and biotech customers with both synthetic and recombinant peptide capabilities. Most directly comparable to Genovior's fully synthetic peptide platform and GLP-1 ambitions.
- CordenPharma: Global CDMO with strong peptide manufacturing and sterile injectable capabilities, including complex formulations. Comparable to Polaris's Genovior platform across peptides and sterile fill-finish.
- PolyPeptide Group: Switzerland-based peptide CDMO specializing in custom synthesis of therapeutic peptides for clinical and commercial supply. Direct peer to Polaris/Genovior for peptide API and GMP manufacturing.
Broad incumbents
- Lonza Group: World's largest biologics CDMO offering mammalian and microbial expression, peptide manufacturing and fill-finish across global sites. Comparable to Polaris as a biologics/peptide CDMO, though Lonza is far larger and more diversified.
Regional players
- Bora Pharmaceuticals: Taiwan-based CDMO offering oral solid dose and complex injectables manufacturing with global footprint. Direct regional peer to Polaris/Genovior for Asia-Pacific CDMO services.
Emerging players
- Tanvex Biologics: Taiwan-based biologics manufacturer with biosimilar pipeline and US BLA experience. Comparable as a Taiwan-headquartered biologics manufacturer targeting US regulatory approval, though with different therapeutic focus.
- BeiGene: Global oncology company headquartered in China with commercial-stage hematology and solid tumor drugs. Comparable as an Asia-rooted oncology developer with global commercial ambitions and manufacturing footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Polaris Pharmaceuticals social profiles
Digital presencePolaris Pharmaceuticals compliance and trust
Trust signalCompliance10 records
Polaris Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Polaris Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles8 records
Polaris Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries7 records
Polaris Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Polaris Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Polaris Pharmaceuticals
What does Polaris Pharmaceuticals do?
Polaris Group is a multinational biopharmaceutical company developing ADI-PEG 20 (Pegargiminase/ADZODI), a first-in-class pegylated arginine deiminase biologic that selectively starves ASS1-deficient cancer cells of arginine. The drug is in late-stage clinical development across multiple oncology indications (malignant pleural mesothelioma, hepatocellular carcinoma, soft tissue sarcoma, glioblastoma, acute myeloid leukemia) and NASH. The company also operates a CDMO business through Genovior Biotech and DesigneRx Pharmaceuticals providing peptide API and sterile injectable contract manufacturing services.
Is Polaris Pharmaceuticals a public or private company?
Polaris Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Polaris Pharmaceuticals founded?
Polaris Pharmaceuticals was founded in 2006. It employs 51 to 100 people.
Where is Polaris Pharmaceuticals based?
Polaris Pharmaceuticals is headquartered in San Diego, United States, in the North America region.
How does Polaris Pharmaceuticals make money?
Four revenue lines are on record. New Drug Development (ADI-PEG 20) is the primary driver. The others are regional Licensing and Distribution Revenue, CDMO Services (Genovior and DesigneRx) and fulvestrant Commercialization (Genovior/MNR).
Who are Polaris Pharmaceuticals's main competitors?
Direct peers on record are AGC Biologics, Samsung Biologics, WuXi Biologics, Bachem Holding AG, CordenPharma and PolyPeptide Group. Lonza Group is listed as a broad incumbent. Bora Pharmaceuticals is listed as a regional player. Emerging players are Tanvex Biologics and BeiGene.
Does Polaris Pharmaceuticals have an API?
No public API is recorded for Polaris Pharmaceuticals.
What industry is Polaris Pharmaceuticals in?
Polaris Pharmaceuticals's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325414 and its SIC code is 2836.